SPECTRUM PHARMACEUTICALS INC (SPPI)

US84763A1088 - Common Stock

1.03  0 (0%)

After market: 1.04 +0.01 (+0.97%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

SPECTRUM PHARMACEUTICALS INC

NASDAQ:SPPI (7/31/2023, 7:00:02 PM)

After market: 1.04 +0.01 (+0.97%)

1.03

0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap211.40M
Shares
PEN/A
Fwd PE7.97
Dividend Yield0%
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

SPPI Daily chart

Company Profile

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. The company is headquartered in Henderson, Nevada and currently employs 86 full-time employees. The firm is focused on acquiring, developing, and commercializing targeted oncology therapies. The firm's product portfolio consists of one commercial product and product candidates for the treatment of cancer patients. Its commercial product candidate includes ROLVEDON (eflapegrastim), which is a long-acting granulocyte colony-stimulating factor (G-CSF) that employs a proprietary LAPSCOVERY technology designed to enhance the duration of therapeutic effects and reduce the frequency of administration. ROLVEDON is FDA-approved for the treatment of adult patients with chemotherapy-induced neutropenia. Its development pipeline includes Poziotinib is a novel, pan-HER inhibitor that is designed to irreversibly block signaling through the Epidermal Growth Factor Receptor (EGFR) family of TKIs, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.

Company Info

SPECTRUM PHARMACEUTICALS INC

11500 S Eastern Ave Ste 240

Henderson NEVADA 89052

P: 17028356300.0

CEO: Joseph W. Turgeon

Employees: 86

Website: https://www.sppirx.com/

SPPI News

News Image8 months ago - Spectrum Pharmaceuticals, Inc.Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.
News Image9 months ago - Halper Sadeh LLPIMPORTANT ALERT: Halper Sadeh LLC Investigates FOCS, ASRT, MDWT, SPPI

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image9 months ago - Kahn Swick & Foti, LLCSPECTRUM PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Spectrum Pharmaceuticals, Inc. - SPPI
News Image11 months ago - Spectrum Pharmaceuticals, Inc.Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
News Imagea year ago - AB NewswireUndervalued Biotech Stocks to Watch After Enzolytics’ (OTC:ENZC) 300% Run: RMED, SPPI, HALB, VXRT
News Imagea year ago - Seeking AlphaSpectrum Pharmaceuticals GAAP EPS of -$0.02 beats by $0.03, revenue of $15.6M beats by $1.44M (NASDAQ:SPPI)

Spectrum Pharmaceuticals press release (NASDAQ:SPPI): Q1 GAAP EPS of -$0.02 beats by $0.03.Revenue of $15.6M beats by $1.44M.

SPPI Twits

Here you can normally see the latest stock twits on SPPI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example